Biomarkers Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024-2030)

Biomarkers Market Size

Biomarkers Market Analysis

Consumables Category Has Largest Market Size

Based on product type, the consumables category accounted for the largest share, of 70%, in the market in 2022, due to the rising demand for kit-based products for biomarker testing and the frequent purchase of consumables. Additionally, advanced consumable products are being made available for healthcare professionals for early diagnosis and better patient compliance.

Moreover, the software category will show the fastest growth in the biomarkers market due to the rapid adoption of software-based approaches in diagnostic labs for the accurate and early diagnosis of disease. The key areas software-based biomarkers are used in include gene sequencing, drug discovery, and pharmacodynamic evaluation. Additionally, the growth of this category is attributable to the increasing adoption of smartphones and wearable devices by patients, which aids in physiological data collection. The software-based technology makes it simple to transfer and analyze the data gathered from biosensors.

Safety Biomarkers Accounted for Largest Share

Based on type, the safety biomarkers category accounted for the largest revenue share, of 55%, in 2022, and it is further expected to maintain its dominance in the future. This is credited to an increase in the population who is at risk of cancer, cardiovascular ailments, and kidney disorders, as well as the rise in the understanding of the value of routine health examinations. Moreover, the frequent non-compliance to the drug regimen, including failure to take the dose or taking an incorrect dose, is propelling the category.

The usage of safety molecular biomarkers in preclinical trials is also increasing, to help identify drug candidates that are expected to be well-tolerated by humans. This decreases the time and resources needed for preclinical safety reviews during the drug development process.

Whereas, the efficacy biomarkers category will witness the fastest growth during the prediction period. This will be owing to the ability of these agents to evaluate the therapeutic efficacy of drug products, which is why such markers are rapidly increasing in adoption in the pharmaceutical and biotechnology industries for drug discovery.

Moreover, the validation biomarkers category is showing significant growth owing to the use of these biomarkers to predict the therapeutic failure of pharmaceutical compounds with weak therapeutic profiles and distinctive genetic profiles. For instance, in January 2020, Biocept Inc. unveiled a target selector platform and assays enabling medical professionals to examine circulating tumor cells and biomarkers linked to breast/lung cancer in the cerebrospinal fluid.

Drug Discovery & Development To Grow Fastest

Based on application, the drug discovery & development category is expected to grow with fastest CAGR in the future. This is because pharmaceutical and biotechnology companies are focusing on setting up state-of-the-art R&D facilities for the development of targeted drugs, easier drug efficacy prediction capabilities, and a quick approval process. Moreover, with the help of these agents, it is possible to classify patient groups, calculate the degree to which new medication hits its target, alter hypothesized pathophysiological processes, and achieve the desired therapeutic effects.

Whereas, the diagnostics category holds largest share, owing to the benefits of biomarkers in early disease identification, which offers the diagnostic sector a chance to advance early diagnosis and improve treatment success rates. For instance, biomarkers have made COVID-19 identification and treatment easier. Moreover, diagnostic biomarker kits are widely used in laboratories for several diagnostic purposes. Thus, innovative non-invasive methods that utilize such markers as diagnostic tools are expected to be a key driver for the industry in this category.

Thus, in May 2021, in order to increase its offerings of precision medicines and biomarkers for lung cancer, QIAGEN N.V. recently announced the release of its tissue companion diagnostic solutions, which are approved by the FDA, to detect the KRAS G12C mutation in non-small-cell lung cancer patients.

Geographical Analysis

Geographically, North America accounted for the largest share, of around 40%, in 2022, and it is set to grow at a robust CAGR during the review period. The large share of this region can be attributed to the growing use of such markers in personalized medicine and various business expansion strategies adopted by the market players, such as partnerships and collaborations with established pharmaceutical and biotechnological companies in this region.

For instance, in September 2020, Thermo Fisher Scientific signed a collaboration bond with the University of Nebraska Medical Center and AstraZeneca to create new approaches to tackle the problems associated with the identification of clinical biomarkers. Furthermore, the high adoption rate of biological markers in the region for disease diagnostics, majorly for cancer, drives the market.

In Canada, the developed healthcare infrastructure, growth in consumers’ knowledge of early disease detection, and the robust support of the government for technological advancements in the space drive the market growth. For instance, in 2020, the Canadian government invested USD 1,000,000 in a research project aimed at finding biomarkers for COVID-19 severity detection.

Moreover, Europe is the second-largest biomarkers market, due to the presence of prominent research institutions and market players. Additionally, the expansion of the partnerships between research institutions and providers of biomarker solutions for diagnostics is responsible for the market expansion.

Furthermore, Germany is showing significant growth in the adoption of these markers, as it has a developed healthcare infrastructure and favorable government policies for biomarker development and usage. Moreover, the adoption of specialized approaches for the treatment of cancer, driven by extensive R&D, and the presence of major hospitals, research centers, and clinics are contributing to the market growth. Additionally, a large number of cancer centers and hospitals have been established in the region, which is driving the usage of biomarkers for oncology research and tumor diagnosis.

Report Breakdown

Based on Application

• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment

Based on Product Type

• Consumables
• Services
• Software

Based on Type

• Safety
• Efficacy
• Validation

Based on Disease

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Immunological Disorders
• Renal Disorders

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Top Biomarkers Companies